Abivax SA
Company Profile
Business description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Contact
7-11 boulevard Haussmann
Paris75009
FRAT: +33 153830963
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
69
Stocks News & Analysis
stocks
This ASX miner is the cheapest in our iron ore coverage
stocks
Apple names new CEO as Tim Cook steps aside after 15 years
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,084.70 | 40.50 | -0.44% |
| CAC 40 | 8,235.72 | 95.32 | -1.14% |
| DAX 40 | 24,270.87 | 146.93 | -0.60% |
| Dow JONES (US) | 49,149.38 | 293.18 | -0.59% |
| FTSE 100 | 10,498.09 | 110.99 | -1.05% |
| HKSE | 26,133.61 | 353.87 | -1.34% |
| NASDAQ | 24,259.96 | 144.43 | -0.59% |
| Nikkei 225 | 59,531.56 | 182.39 | 0.31% |
| NZX 50 Index | 12,945.60 | 13.27 | 0.10% |
| S&P 500 | 7,064.01 | 45.13 | -0.63% |
| S&P/ASX 200 | 8,856.20 | 40.60 | -0.46% |
| SSE Composite Index | 4,101.00 | 15.92 | 0.39% |